Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 10, 2023, titled "Zydus and Torrent sign licensing agreement for co-marketing Saroglitazar Mg, a critical treatment for chronic liver diseases in India".
Press Release Nov 10 2023
Filed with NSE · · 4 pages · English
Summary by 6ix AI
This innovative drug is the only approved treatment for Non-Alcoholic Steato Hepatitis and Non-Alcoholic Fatty Liver Disease in the country. Under the agreement, Torrent will market the drug under the brand name VORXAR, while Zydus will continue to market it under its existing brand names.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Nov 07 2023
- Press Release Nov 06 2023
- Press Release Nov 03 2023
- Press Release Nov 02 2023
- Press Release Oct 31 2023
Later from Zydus Lifesciences
- Press Release Dec 01 2023
- Zydus Lifesciences Limited Press Release Dec 06 2023
- Zydus Lifesciences Limited Press Release Dec 11 2023
- Press Release Dec 14 2023
- Press Release Dec 15 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences